Floatz logo

Chimeric Antigen Receptor Modified T Cells Infusion

Myelodysplastic Syndromes

Zhujiang HospitalCell therapyPhase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

315 Active assets in the Myelodysplastic Syndromes cohort.

Asset / SponsorPhaseRating
Fludarabine
Sawa Ito, MD
Phase 4BB
Anti-Thymoglobulin, Rabbit
Peking University First Hospital
Phase 2/3BB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 4BB
FILGRASTIM
City of Hope Medical Center
Phase 4BB
Daunorubicin
OHSU Knight Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:

B Cell LymphomaDormant
BB
Indicative ·
71 / 100
View asset →
Non Hodgkin LymphomaDormant
BB
Indicative ·
67 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →